Savient Nuflexxa Approval For Knee Arthritis May Aid Sale Of BTG Unit
This article was originally published in The Gray Sheet
Executive Summary
Savient Pharmaceuticals' planned divestiture of its Bio-Technology General unit to fund drug R&D could get a boost from PMA approval of its hyaluronic acid injection for knee osteoarthritis, announced Dec. 7